Legend Biotech Corporation (LEGN)

US — Healthcare Sector
Peers: PCVX  APLS  TVTX  AKRO  ISEE  BPMC  AMLX  KRTX  DAWN  ZLAB  SGEN  ALNY  ASND  ETNB  MDGL  PLRX  ACLX  STOK  MRTX  TERN 

Automate Your Wheel Strategy on LEGN

With Tiblio's Option Bot, you can configure your own wheel strategy including LEGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LEGN
  • Rev/Share 3.9633
  • Book/Share 5.5384
  • PB 2.6136
  • Debt/Equity 0.3565
  • CurrentRatio 5.2002
  • ROIC -0.1885

 

  • MktCap 2663819659.0
  • FreeCF/Share -1.4865
  • PFCF -9.7516
  • PE -12.1934
  • Debt/Assets 0.2246
  • DivYield 0
  • ROE -0.2014

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation LEGN Redburn Atlantic -- Buy -- $86 Oct. 8, 2024

News

Shareholder Rights Advocates at Levi & Korsinsky Investigate Legend Biotech Corporation (LEGN) Regarding Possible Securities Fraud Violations
LEGN
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Read More
image for news Shareholder Rights Advocates at Levi & Korsinsky Investigate Legend Biotech Corporation (LEGN) Regarding Possible Securities Fraud Violations
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
LEGN
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology Association's (EHA) Congress. Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors, specifically lung and gastric cancers respectively, will also be featured in poster presentations at ASCO.

Read More
image for news Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money
LEGN
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Read More
image for news LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money
LEGN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Legend Biotech Corporation
LEGN
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Read More
image for news LEGN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Legend Biotech Corporation
Legend Biotech Corporation Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - LEGN
LEGN
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Read More
image for news Legend Biotech Corporation Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - LEGN
LEGN ALERT: Levi & Korsinsky Investigates Legend Biotech Corporation for Possible Securities Fraud Violations
LEGN
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Read More
image for news LEGN ALERT: Levi & Korsinsky Investigates Legend Biotech Corporation for Possible Securities Fraud Violations
Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript
LEGN
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - Chief Executive Officer Jessie Yeung - Interim Chief Financial Officer Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Yaron Werber - TD Cowen Kostas Biliouris - BMO Capital Jonathan Miller - Evercore ISI Leonid Timashev - RBC James Shin - Deutsche Bank Mitchell Kapoor - H.C. Wainright Jeet Mukherjee - BTIG Ashwani Verma - …

Read More
image for news Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript
What Makes Legend Biotech (LEGN) a New Buy Stock
LEGN
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news What Makes Legend Biotech (LEGN) a New Buy Stock
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
LEGN
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
LEGN
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Read More
image for news Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

About Legend Biotech Corporation (LEGN)

  • IPO Date 2020-06-05
  • Website https://www.legendbiotech.com
  • Industry Biotechnology
  • CEO Dr. Ying Huang Ph.D.
  • Employees 2600

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.